The preference for sugar over sweetener depends on a gut sensor cell

Kelly L. Buchanan1,2,13, Laura E. Rupprecht1,3,13, M. Maya Kaelberer1,3,13, Atharva Sahasrabudhe4,5,6, Marguerita E. Klein1,3, Jorge A. Villalobos1,3, Winston W. Liu1,2,7, Annabelle Yang1,8, Justin Gelman1,8, Seongjun Park1,3, Jorge A. Villalobos1,3, Winston W. Liu1,3,11,12.

Guided by gut sensory cues, humans and animals prefer nutritive sugars over non-caloric sweeteners, but how the gut steers such preferences remains unknown. In the intestine, neuropod cells synapse with vagal neurons to convey sugar stimuli to the brain within seconds. Here, we found that cholecystokinin (CCK)-labeled duodenal neuropod cells differentiate and transduce luminal stimuli from sweeteners and sugars to the vagus nerve using sweet taste receptors and sodium glucose transporters. The two stimulus types elicited distinct neural pathways: while sweetener stimulated purinergic neurotransmission, sugar stimulated glutamatergic neurotransmission. To probe the contribution of these cells to behavior, we developed optogenetics for the gut lumen by engineering a flexible fiberoptic. We showed that preference for sugar over sweetener in mice depends on neuropod cell glutamatergic signaling. By swiftly discerning the precise identity of nutrient stimuli, gut neuropod cells serve as the entry point to guide nutritive choices.
when infused into the intestine\(^9\). Control experiments showed that the vagal responses to sugars and sweeteners were not due to mechanical forces or osmolarity effects, as volume-matched normal PBS (200 μl), osmolarity-matched mannitol (650 mosM) or high-concentration PBS (650 mosM) did not elicit an increase in vagal firing (Extended Data Fig. 1c). Moreover, vagal responses to sugar and sweetener were confined to the small intestine. A vagal response to sucrose was only observed when infused into the duodenum and ileum but not the colon (Extended Data Fig. 1d,e). It is expected that glucose sensing occurs primarily in the proximal small intestine. This portion of the intestine is responsible for the postigestive rewarding effects of glucose\(^9\,10\) and is where the vast majority of glucose is absorbed.

The vagal response depends on duodenal neuropod cells. We hypothesized that the vagal responses depended on signals emanating from the intestinal epithelium. Vagal nodose neurons did not respond to sugars when isolated and cultured in vitro. Of all neurons imaged, 98.3% showed no calcium transients in response to sugars or sweeteners (Extended Data Fig. 2c). Thus, duodenal neuropod cells discern sugar from sweetener.

Duodenal neuropod cells discern sugar from sweetener. We next tested how individual CCK-labeled neuropod cells respond to sugar and sweetener. Calcium transients were imaged in individual neuropod cells labeled with tdTomato (CckCRE\_tdTomato) using the calcium indicator dyes Fluo-4 and Fura Red. A positive response was defined as an increase in the fluorescence ratio (Fluo-4/Fura Red) by greater than 10% (see Methods). In the 26 cells that responded to at least one sugar, 53.8% of cells responded to d-glucose only (20 mM), 15.4% to sucrose only (2 mM) and 30.8% to both d-glucose and sucrose (N = 3 mice, n = 47 viable cells; viability confirmed with KCl (50 mM); Fig. 3a).

Single-cell RT–qPCR was then used to determine the expression of molecular receptors used to sense sugars and sweeteners on individual CCK-labeled neuropod cells. Intestinal epithelial cells absorb d-glucose after it is cleaved from sucrose through active transport mediated by SGLT1\(^15\). In addition, some intestinal epithelial cells...
also express sweet taste receptors. Vagal neurons, however, do not express transcripts for these sugar receptors (Extended Data Fig. 2). Although SGLT1 and sweet taste receptors are known to be expressed in intestinal epithelial cells, the expression profile of these receptors on individual CCK-labeled neuropod cells is unknown. We collected the small intestinal epithelial layers of mice expressing green fluorescent protein (GFP) under the CCK promoter (CCK–GFP) and performed RT–qPCR on single cells.

Compared to non-GFP cells, CCK–GFP cells were enriched in genes associated with synapse formation and vesicular function or release (N = 3 mice; n = 198 cells, 132 CCK–GFP compared to non-GFP cells; q value cutoff <0.05 by two-tailed t-test; Fig. 3b; fold changes and P values for each gene are shown in Extended Data Fig. 3p). Moreover, individual CCK–GFP cells expressed SGLT1 and sweet taste receptors (Fig. 3b and Extended Data Fig. 3a). Immunohistochemistry was used to corroborate the presence of SGLT1 protein in the small intestine including CCK–GFP cells. Immunostaining of SGLT1 was prominent in the small intestine where sugars are absorbed compared to in the colon where minimal staining was observed (N = 3 mice; Extended Data Fig. 3bc).

Receptor expression in individual CCK–GFP cells was as follows: Tas1r2 was negligible, Tas1r3 alone was in 1.2% (±1.2%) of cells, the SGLT1 transcript Slc5a1 alone was in 60.1% (±5.7%) of cells and both Tas1r3 and Slc5a1 were in 19.6% (±4.3%) of cells (N = 3 mice, n = 132 CCK–GFP cells; Fig. 3c). These data were confirmed using fluorescence in situ hybridization in duodenal tissue from CCK–GFP mice, where Slc5a1 alone was in 71.3% (±0.04%) of cells, and both Slc5a1 and Tas1r3 were in 28.7% (±0.04%) of cells (N = 3 mice, n = 50 cells per mouse; Extended Data Fig. 3d,e). Negligible transcript expression of Tas1r2 suggests that TIR3 may function alone to detect sweet taste in CCK-labeled neuropod cells. While TIR2/TIR3 is the primary sensor of sweet stimuli in taste receptor cells, TIR3 homodimers in taste receptor cells can also detect sweet stimuli. Other sensory epithelial cells, including GLP-1-secreting enteroendocrine cells and pancreatic beta cells, have been shown to respond to sweet molecules using only TIR3.

We then determined if individual CCK–GFP cells with transcripts for SGLT1 (Slc5a1) and TIR3 (Tas1r3) also expressed synaptic transcripts, which is a distinctive feature of neuropod cells. Compared to other CCK–GFP cells lacking the expression of Slc5a1, Slc5a1–expressing CCK–GFP cells had significantly increased expression of the presynaptic genes Efnb2 (fold change of 81.6) and Cask (fold change of 30.2) and the synaptic adhesion genes Pvr1 (fold change of 31.05) and Pvr2 (fold change of 35.2) (N = 3 mice; n = 104 Slc5a1–CCK–GFP cells, n = 28 Slc5a1–CCK–GFP cells; P < 0.0001; Extended Data Fig. 3h). Compared to CCK–GFP cells lacking the expression of Tas1r3, Tas1r3–expressing CCK–GFP cells were also enriched in the expression of Efnb2 (fold change of 189.7), Cask (fold change of 24.76), Pvr1 (fold change of 32.2) and Pvr2 (fold change of 37.2) (N = 3 mice; n = 101 Tas1r3–CCK–GFP cells, n = 101 Tas1r3–CCK–GFP cells; P < 0.0001; Extended Data Fig. 3i). These data show that CCK–GFP cells expressing Slc5a1 and Tas1r3 also express transcripts of proteins necessary for synaptic signaling.

Next, we assessed if the vagal responses to sugars or sweeteners were mediated by epithelial SGLTs or TIR3. When cleaved from sucrose, D-glucose enters the cell through SGLT1 for further metabolism. The synthetic analog α-MGP also enters the cell through SGLT1 but is not further metabolized. As such, its use allows for isolation of the entry of sugar into the cell through SGLT1. The results show that vagal responses to both sucrose and α-MGP are abolished when SGLTs are blocked with phloridzin (3 mM) (N ≥ 5 mice; P < 0.03 compared to preinhibition response; Fig. 3d,e). Phloridzin can also act at SGLT2, but inhibiting SGLT2 with dapagliflozin (3 mM) had no effect on the vagal response to sucrose (N = 3 mice; not significant compared to preinhibition response; Extended Data Fig. 3f). Single-cell RT–qPCR data showed no expression of the SGLT2 transcript Slc5a2 in gut epithelial cells (Fig. 3b).

As expected, the SGLT inhibitor phloridzin did not affect the response to luminal sucralose (N ≥ 5 mice; not significant compared to preinhibition response; Fig. 3d,e). Instead, blocking sweet taste receptors, including TIR3, with curcumin (7 μM) abolished the vagal response to sucrose (N ≥ 5 mice; P > 0.03 compared to preinhibition response; Fig. 3d,e). Curcumin (7 μM), however, did not affect the response to sucrose (300 mM) or α-MGP (150 mM) (N ≥ 5 mice; not significant compared to preinhibition response; Fig. 3d,e). These data differ from the studies of taste transduction in the tongue, where both sucrose and sucralose activate TIR2/TIR3 receptors. In the gut, only sucralose elicited a taste receptor-mediated vagal response. The difference may be explained by the lack of expression of TIR2 in CCK-labeled neuropod cells and implies that TIR3 in the gut is more sensitive to sucralose than sucrose.
Sugar, not sweetener, elicits glutamatergic neurotransmission.

We then determined how duodenal CCK-labeled neuropod cells communicate different intestinal stimuli to the vagus nerve. d-Glucose stimulates individual neuropod cells to release glutamate \(^{14}\). CCK–GFP cells express transcripts for the vesicular glutamate transporters Slc17a7 and Slc17a8 and the synaptic glutamate transporters Slc1a1, Slc1a2 and Slc1a3 (Fig. 3b). Using intestinal organoids, we probed whether glutamate release is (1) specific to sugar and not sweetener and (2) conserved between mice and humans. Organoids were cultured from mouse proximal small intestine \(^{28}\) and human duodenum \(^{29}\). Sucrose (300 mM) and completely attenuated the response to α-MGP (150 mM) (Fig. 4a,b). In CckCRE_tdTomato cells loaded with Fluo-4/Fura Red dye, calcium activity was measured (Fig. 3a,b). F-Ratio, fluorescence intensity ratio of Fluo-4 divided by Fura Red. AU, arbitrary units. b, Heat map of gene expression in CCK–GFP and non-GFP intestinal epithelial cells by single-cell real time quantitative PCR (single cell RT–qPCR). Compared to non-GFP cells (n = 66), CCK–GFP cells (n = 132) overexpress genes associated with synapse formation (Amigo1, Polo, Syn1-Syn3) and genes associated with vesicular function/release (Cplx1, Syp, Snap25, Stxbp1) (N = 3 mice; fold changes and P values are shown in Extended Data Fig. 3d). c, Of 132 CCK–GFP cells, 19.1 ± 0.02 compared to preinhibition response; Fig. 4a,b and Extended Data Fig. 4g). However, glutamatergic inhibition had no effect on the vagal response to sucrose and completely attenuated the response to α-MGP (N = 11 and 5; P < 0.02 compared to preinhibition response; Fig. 4a,b and Extended Data Fig. 4g). Therefore, the entry of sugar into the cell drives glutamatergic neurotransmission between neuropod cells and vagal neurons.

In addition to neurotransmission, there is a CCK hormonal signal emanating from duodenal CCK-labeled neuropod cells. Vagal neurons express the CCK-A receptor (Extended Data Fig. 4d). Therefore, we tested a potential role of CCK hormone in vagal

Transcripts for both metabotropic and ionotropic glutamate receptors are expressed in vagal nodose neurons (Extended Data Fig. 4d) \(^{14}\). Blocking ionotropic and metabotropic glutamate receptors with intraluminal perfusion of kynurenic acid (KA) (150 μg kg\(^{-1}\)) plus 1,2-amino-3-phosphonopropionic acid (AP3) (1 mg kg\(^{-1}\)), respectively, decreased the early phase of the vagal response to sucrose and completely attenuated the response to α-MGP (N = 11 and 5; P < 0.02 compared to preinhibition response; Fig. 4a,b and Extended Data Fig. 4g). However, glutamatergic inhibition had no effect on the vagal response to sucrose (N = 6 mice; not significant compared to preinhibition response; Fig. 4a,b and Extended Data Fig. 4g). Notably, inhibiting glutamatergic neurotransmission eliminated the α-MGP response (Fig. 4a,b and Extended Data Fig. 4g). Therefore, the entry of sugar into the cell drives glutamatergic neurotransmission between neuropod cells and vagal neurons.

In addition to neurotransmission, there is a CCK hormonal signal emanating from duodenal CCK-labeled neuropod cells. Vagal neurons express the CCK-A receptor (Extended Data Fig. 4d). Therefore, we tested a potential role of CCK hormone in vagal

Sugar, not sweetener, elicits glutamatergic neurotransmission.

We then determined how duodenal CCK-labeled neuropod cells communicate different intestinal stimuli to the vagus nerve. d-Glucose stimulates individual neuropod cells to release glutamate \(^{14}\). CCK–GFP cells express transcripts for the vesicular glutamate transporters Slc17a7 and Slc17a8 and the synaptic glutamate transporters Slc1a1, Slc1a2 and Slc1a3 (Fig. 3b). Using intestinal organoids, we probed whether glutamate release is (1) specific to sugar and not sweetener and (2) conserved between mice and humans. Organoids were cultured from mouse proximal small intestine \(^{28}\) and human duodenum \(^{29}\). Sucrose (300 mM) and completely attenuated the response to α-MGP (150 mM) (Fig. 4a,b). In CckCRE_tdTomato cells loaded with Fluo-4/Fura Red dye, calcium activity was measured (Fig. 3a,b). F-Ratio, fluorescence intensity ratio of Fluo-4 divided by Fura Red. AU, arbitrary units. b, Heat map of gene expression in CCK–GFP and non-GFP intestinal epithelial cells by single-cell real time quantitative PCR (single cell RT–qPCR). Compared to non-GFP cells (n = 66), CCK–GFP cells (n = 132) overexpress genes associated with synapse formation (Amigo1, Polo, Syn1-Syn3) and genes associated with vesicular function/release (Cplx1, Syp, Snap25, Stxbp1) (N = 3 mice; fold changes and P values are shown in Extended Data Fig. 3d). c, Of 132 CCK–GFP cells, 19.1 ± 0.02 compared to preinhibition response; Fig. 4a,b and Extended Data Fig. 4g). However, glutamatergic inhibition had no effect on the vagal response to sucrose and completely attenuated the response to α-MGP (N = 11 and 5; P < 0.02 compared to preinhibition response; Fig. 4a,b and Extended Data Fig. 4g). Notably, inhibiting glutamatergic neurotransmission eliminated the α-MGP response (Fig. 4a,b and Extended Data Fig. 4g). Therefore, the entry of sugar into the cell drives glutamatergic neurotransmission between neuropod cells and vagal neurons.

In addition to neurotransmission, there is a CCK hormonal signal emanating from duodenal CCK-labeled neuropod cells. Vagal neurons express the CCK-A receptor (Extended Data Fig. 4d). Therefore, we tested a potential role of CCK hormone in vagal
responses to sucrose and sucralose. Blocking CCK-A receptors with devazepide (2 mg kg$^{-1}$)$^{30}$ blunted vagal response to sucrose 2 min after the onset of stimulus, leaving the first 120 s of the response intact. However, blocking CCK-A receptors did not affect the vagal response to sucralose ($N=5–6$ mice; not significant compared to preinhibition response; Extended Data Fig. 4e,f,i). Therefore, the vagal response to sucralose was both glutamate and CCK independent.

We explored the possibility that sweetener may be transduced using a different neurotransmitter. In the tongue, taste receptor cells release ATP to activate purinergic receptors on sensory neurons in response to sweet stimuli$^{11}$. Additionally, it has been shown that proglucagon-labeled enteroendocrine cells co-release hormone with the fast neurotransmitter ATP$^{32}$. Thus, ATP was a candidate neurotransmitter for sucralose in the gut. We found that nodose neurons expressed purinergic receptors and that candidate neurotransmitter for sucralose in the gut. We found that nodose neurons expressed purinergic receptors and that candidate neurotransmitter for sucralose in the gut. We found that nodose neurons expressed purinergic receptors and that candidate neurotransmitter for sucralose in the gut. We found that nodose neurons expressed purinergic receptors and that candidate neurotransmitter for sucralose in the gut. We found that nodose neurons expressed purinergic receptors and that candidate neurotransmitter for sucralose in the gut. We found that nodose neurons expressed purinergic receptors and that candidate neurotransmitter for sucralose in the gut. We found that nodose neurons expressed purinergic receptors and that candidate neurotransmitter for sucralose in the gut. We found that nodose neurons expressed purinergic receptors and that candidate neurotransmitter for sucralose in the gut.
A flexible fiber for gut optogenetics. Now that it was established that neuropod cells discern sugar from sweetener, we sought to determine whether these epithelial transducers also guide the animal’s preference for sugar over sweetener. To test the contribution of these cells to behavior, a method was needed to silence neuropod cells while the mouse’s preference was recorded.

In the brain, the contribution of specific neurons to behaviors has been uncovered using optogenetics. This technique relies on light-gated channels activated by laser light traditionally delivered using rigid silica fiberoptics. In the gut, however, we found that rigid fiberoptics puncture and perforate the intestinal wall. Recently, some efforts have been made to stimulate the outer muscular wall of the intestine or a small portion of the stomach in vivo. But no tool existed to control a specific population of gut epithelial cells diffused along several centimeters of the intestinal lumen in a living animal. As such, we developed a new device to deliver laser light into the gut lumen.

The system required a flexible fiberoptic with the following properties: (1) thin diameter for minimal footprint within the intestinal lumen, (2) low optical loss coefficient to deliver light to the gut lumen, (3) efficient light transmission even when bent and (4) durability for months when folded inside the chewing gut. First, we engineered a fiber preform of a poly-methyl methacrylate (PMMA) cladding layer around an optical core of polycarbonate (PC). Then, the preform was thermally drawn at 270°C into a final flexible fiber 230 μm in diameter (Fig. 5a,b). To determine optical loss, the fiber was cut in 0.5-cm increments, and light transmission was measured when the fiber was either straight or bent to 180°. Percent transmission was compared to transmission at the shortest length. The loss coefficients were determined to be 0.93 dB cm⁻¹ and 1.30 dB cm⁻¹ for straight and bent fibers, respectively (Fig. 5c).

Light transmission had minimal loss when bent at 90°, 180° and 270° angles compared to transmission when the fiber was held straight (Fig. 5d). Repeated 180° bending did not heavily influence light transmission (Fig. 5e). In addition, the device transmitted light with a 1.2-dB cm⁻¹ loss and tolerated rapid bending at 10 Hz, which is above the physiological frequency of gut motility (Fig. 5f). Compared to rigid silica, the flexible fiberoptic did not pierce through a soft layer of 1.5% agarose, which is similar in consistency to the gut wall (Fig. 5g and Supplementary Video 1). The flexible fiberoptic was opacified to restrict light to the first 1.5 cm of the mouse small intestine (Fig. 5h).

To validate the device for gut optogenetics in freely moving mice, we investigated if silencing CCK-labeled neuropod cells eliminated the anorectic effect of a lipid gavage, an established physiological effect of CCK. A fat solution (intralipid, 7%) was delivered into the gut lumen. Of importance, silencing CCK-labeled neuropod cells decreased sucrose intake and increased sucralose intake, but the total consumption of liquid during the 1-h test was not affected (P < 0.05; Extended Data Fig. 6c). In other words, silencing duodenal neuropod cells eliminated preference for sucrose over sucralose. In posttest controls without laser treatment, mice displayed the same pretest preference for sucrose (Fig. 6b), indicating that the animals did not lose their preference for sucrose but rather their ability to discern the preferred sugar from the sweetener.

To determine whether activating duodenal neuropod cells would increase an animal’s consumption of the non-preferred solution, sucralose, we bred mice in which CCK-labeled neuropod cells expressed channelrhodopsin 2 (CckCRE_ChR2). This excitatory opsin is activated by blue light (473 nm). The mice were pre-injected with one bottle containing sucralose (15 mM), and intake of 0.01 ml triggered a 5-s laser stimulation (5 V, 40 Hz, 20% duty cycle) (Extended Data Fig. 7a). In this assay, 473 nm light had no effect on the intake of wild-type littermates (N = 4; not significant compared to 532-nm control; Extended Data Fig. 7b,c). However, in CckCRE_ChR2 mice, exciting CCK-labeled neuropod cells with 473-nm light significantly increased sucralose intake (N = 4; P < 0.05 compared to 532-nm control; Extended Data Fig. 7b,c). These results indicate that stimulating duodenal neuropod cells drives mice to consume sweetener as if it were sugar.

Sugar preference depends on duodenal neuropod cells. We then determined if CCK-labeled neuropod cells are necessary for mice to discern sucrose from sucralose. Mice were implanted with the flexible fiberoptic, acclimated to the phenotyping cage and tested for side preference. Each mouse was exposed to sucrose and sucralose until they demonstrated a stable preference for sucrose (see Methods). The location and power of the implanted device was corroborated at the end of the study. On each experimental day, implanted mice were given the choice between sucrose (300 mM) and sucralose (15 mM) for 1 h while receiving light stimulation to inhibit CCK-labeled neuropod cells (1 min on/2 min off, 5 V, 40 Hz, 20% duty cycle).

In the presence of 532-nm light, control littermates showed 90.8% (±3.7%) sucrose preference (N = 5 mice; not significant compared to controls; Extended Data Fig. 6a,b), whereas in CckCRE_Halo mice, sucrose preference was only 58.9% (±3.9%) (N = 8 mice; P < 0.01 compared to controls; Fig. 6a,b). In control experiments, silencing duodenal CCK-labeled neuropod cells with 532-nm light did not cause malaise, as neither locomotor activity during the assay (Extended Data Fig. 6d) nor chow or water intake in the following 24 h (Extended Data Fig. 6e,f) were affected. Additional experiments showed that laser inhibition with 532-nm light did not affect gastric emptying of sucrose, total gut transit time or glucose absorption compared to 473-nm control light (Extended Data Fig. 6g–j). Of importance, silencing CCK-labeled neuropod cells decreased sucrose intake and increased sucralose intake, but the total consumption of liquid during the 1-h test was not affected (P = 0.01; Extended Data Fig. 6c).

To test the role of glutamate signaling in preference for sugar over sweetener, we next sought to identify the signaling molecules underlying preference for sugar over sweetener. The effect was not due to local or hormonal CCK signaling because sucrose perfusion through the small intestine did not alter physiological processes controlled by CCK, including gallbladder contraction (Extended Data Fig. 8a) and gastric emptying (Extended Data Fig. 8b). Indeed, blocking CCK-A receptors with intraperitoneal devazepide (2 mg kg⁻¹) during the choice assay did not affect sucrose preference (N = 4; wild-type mice; not significant compared to vehicle controls; Extended Data Fig. 8c–e). This finding supports data from previous studies showing that CCK signaling does not contribute to conditioned sugar preference.

We tested if glutamate signaling is required for CCK-labeled neuropod cells to drive sugar intake. Before gaining access to one bottle of sucrose, CckCRE_ChR2 mice were intraperitoneally injected with ionotropic and metabotropic glutamate receptor blockers (150 μg kg⁻¹ KA/1 mg kg⁻¹ AP3). The increase of sucralose intake driven by optogenetic excitation of CCK-labeled neuropod cells was blocked when glutamate receptors were inhibited (N = 4; P < 0.05; Extended Data Fig. 7d–f). To test the role of glutamate in preference for sugar over sweetener, a catheter was implanted into the duodenal lumen of wild-type mice to deliver a local dose of glutamate receptor blockers (15 ng KA and 0.1 μg AP3 in 0.4 ml; 10,000-fold lower than the dose used in Extended Data Fig. 7d–f). In mice receiving a vehicle control, sucrose preference was 82.4% (±3.2%). Inhibiting glutamate receptor...
signaling from the duodenal lumen significantly reduced sucrose preference to 44.0% (±5.2%) (N = 4; P < 0.05 compared to vehicle controls; Fig. 6d,e). Moreover, local inhibition of glutamatergic signaling also reduced sucrose intake and increased sucrase intake without significant changes in total intake (Fig. 6f). Control experiments showed that this local dose of glutamate receptor blockers did not affect sucrose preference when delivered systemically, confirming its local action in the gut lumen (Extended Data Fig. 9). Therefore, glutamatergic signaling from duodenal neuropod cells enables mice to discern sugar from sweetener.
such stimuli perceived in the minutes before consumption only partially explain our behavior. In the case of sugar, the neurons in the brain driving our preference have received much attention. How we behave in front of sugars depends on a cascade of neuronal activity, including inputs from midbrain neurons that release reinforcing dopamine, hypothalamic melanin-concentrating neurons, brainstem neurons in the caudal nucleus tractus solitarius, and vagal nodose neurons. However, the identity of the cells in the gut that transduce the sensory stimuli to guide the animal’s choices have remained unknown.

Soon after sweet taste receptors were identified, scientists sought to create sweet-blind mice by knocking out taste receptors only to discover that animals were still capable of discerning sugar. Subsequent work has confirmed that oral sweet taste is not essential to drive sugar intake. While duodenal infusions of sweetener and sugar activate separate hindbrain and striatal pathways, only sugar infusions drive a strong conditioned preference. The sugar effects are localized to the proximal small intestine because isolated sugar infusions into the ileum or restricted to the stomach do not condition a strong preference. Recently, it was established that duodenal neuropod cells use the neurotransmitter glutamate to transduce d-glucose from gut to brain. Their contribution to sugar preferences was unknown.

Here, we demonstrate that an animal’s preference for sugar over sweetener depends on duodenal neuropod cells. These cells rapidly transduce such stimuli onto the vagus nerve using two receptors and two neurotransmitters; whereas sweetener activates T1R3 to cause the release of ATP, the entry of sugar into the cell stimulates the release of glutamate. By developing a flexible fiber for gut optogenetics, we discovered that sugar preference depends on duodenal neuropod cells rapidly transducing d-glucose from gut to brain. Their contribution to sugar intake has remained unknown.

**Discussion**

In his classic book *Behave*, the neuroendocrinologist Robert Sapolsky states "What occurred in the prior seconds to minutes that triggered the nervous system to produce the behavior, this is the world of sensory stimuli, much of it sensed unconsciously. While the sight, smell and taste of food change our perception of flavor, such stimuli perceived in the minutes before consumption only partially explain our behavior. In the case of sugar, the neurons in the gut epithelium..."
A major roadblock to study the real-time contribution of a specific gut sensory cell to behavior had been the lack of suitable tools. Unlike olfactory receptor neurons or taste receptor cells, neuroepithelial cells are not clustered in one location. Instead, these cells are scattered throughout the intestinal epithelium. Identifying and manipulating them in freely moving animals is therefore difficult. Pharmacological tools alone are not specific to cell type given the ubiquitous expression of cell surface receptors such as GGLTs. A suitable tool to determine the contribution of specific neuronal cell behavior is optogenetics. Bringing optogenetics to the gut lumen required the development of a new device. The flexible fiberoptic developed here allowed for the use of optogenetics to interrogate the contribution of gut sensations to behavior. We believe this device will allow scientists to determine how behavior is modulated by other viscerally organs that are in constant motion, such as the heart, lung or bladder.

Aided by these technologies, we discovered that the sensory function of neuroepithelial cells is akin to the role of taste receptor cells in detecting tastants so the animal can discern flavor or retinal cone cells in detecting light wavelength so the animal can discern color. Like other sensory transducers11,23,48, neuropod cells use different receptors and transmitters to sense and convey signals from specific stimuli. This work serves as a foundation to determine how other stimuli, such as fats, proteins or microbial molecules, are sensed and transduced in different regions of the intestine to drive appetitive decisions.

Together, the fast neurotransmission and slow endocrine actions of sensor cells provide a synergistic complement for the gut to influence the emotion and logic behind food choices. After all, despite how sweet a food may look, smell or taste, a gratifying experience requires a gut sensation.

Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41593-021-00982-7.

Received: 8 February 2021; Accepted: 9 November 2021; Published online: 13 January 2022

References
1. Damak, S. et al. Detection of sweet and umami taste in the absence of taste receptor T1r3. Science 301, 850–853 (2003).
2. de Araujo, I. E. et al. Food reward in the absence of taste receptor signaling. Neuron 57, 930–941 (2008).
3. Ren, X. et al. Nutrient selection in the absence of taste receptor signaling. J. Neurosci. 30, 8012–8023 (2010).
4. Booth, D. A. Satiety and behavioral caloric compensation following intragastric glucose loads in the rat. J. Comp. Physiol. Psychol. 78, 412–423 (1972).
5. Duan, M., Min, S. H., Keene, A. C., Lee, G. Y. & Suh, G. S. B. Taste-independent detection of the caloric content of sugar in Drosophila. Proc. Natl Acad. Sci. USA 108, 11644–11649 (2011).
6. Sclafani, A. & Ackroff, K. Flavor preferences conditioned by nutritive and non-nutritive sweeteners in mice. Physiol. Behav. 173, 188–199 (2017).
7. Sclafani, A., Cardieri, C., Tucker, K., Blusk, D. & Ackroff, K. Intragastric glucose but not fructose conditions robust flavor preferences in rats. Am. J. Physiol. Integr. Comp. Physiol. 265, R320–R325 (1993).
8. Zukerman, S., Ackroff, K. & Sclafani, A. Rapid post-oral stimulation of intake and flavor conditioning by glucose and fat in the mouse. Am. J. Physiol. Integr. Comp. Physiol. 301, R1635–R1647 (2011).
9. Han, W. et al. Striatal dopamine links gastrointestinal reouting to altered sweet appetite. Cell Metab. 23, 103–112 (2016).
10. Ackroff, K., Yim, Y. M. & Sclafani, A. Post-oral infusion sites that support glucose-conditioned flavor preferences in rats. Physiol. Behav. 99, 402–411 (2010).
11. Buck, L. & Axel, R. A novel multigene family may encode odorant receptors: a molecular basis for odor recognition. Cell 65, 175–187 (1991).
12. Lindemann, B. Receptors and transduction in taste. Nature 413, 219–225 (2001).
13. Kaelberer, M. M., Rupprecht, L. E., Liu, W. W., Weng, P. & Bohorquez, D. V. Neuroepithelial cells: emerging biology of the gut-brain sensory transduction. Annu. Rev. Neurosci. 43, 337–353 (2020).
14. Kaelberer, M. M. et al. A gut-brain neural circuit for nutrient sensory transduction. Science 361, eaax5236 (2018).
15. Bellono, N. W. et al. Enterochromaffin cells are gut chemosensors that couple to sensory neural pathways. Cell 170, 185–198 (2017).
16. Bohorquez, D. V. et al. Neuroepithelial circuit formed by innervation of sensory enterendocrine cells. J. Clin. Invest. 125, 782–786 (2015).
17. Williams, E. K. K. et al. Sensory neurons that detect stretch and nutrients in the digestive system. Cell 166, 209–221 (2016).
18. Sclafani, A. & Ackroff, K. Operand licking for intragastric sugar infusions: differential reinforcing actions of glucose, sucrose and fructose in mice. Physiol. Behav. 153, 115–124 (2016).
19. Crane, R. K., Miller, D. & Bihler, I. The restrictions on possible mechanisms of intestinal transport of sugars. In Membrane Transport and Metabolism. Proceedings of a Symposium held in Prague, August 22–27, 1960 (Ed. Kleinzeller, A. & Kotyk, A.) 439–449 (Czech Academy of Sciences,1960).
20. Dyer, J., Salmon, K. S. H., Zbrik, L. & Shirazi-Beechey, S. P. Expression of sweet taste receptors of the T1R family in the intestinal tract and enteroendocrine cells. Biochem. Soc. Trans. 33, 302–305 (2005).
21. Reimann, F. et al. Glucose sensing in I cells: a primary cell study. Cell Metab. 8, 532–539 (2008).
22. Erlenbach, L., Ryba, N. J. P., Zhao, G., Ryba, N. J. P. & Zuker, C. S. Mammalian T1R3 sweet taste receptors. US patent US0704927 (2008).
23. Nelson, G. et al. Mammalian sweet taste receptors. Cell 106, 381–390 (2001).
24. Ohtsu, Y., Nakagawa, Y., Nagasawa, M., Takeda, S. & Arakawa, H. Diverse signaling systems activated by the sweet taste receptor in human GLP-1-secreting cells. Mol. Cell. Endocrinol. 394, 70–79 (2014).
25. Kojima, I. et al. Glucose-sensing receptor T1R3: a new signaling receptor activated by glucose in pancreatic β-cells. Biol. Pharm. Bull. 38, 674–679 (2015).
26. Ehrenkranz, J. R. L., Lewis, N. G., Kahn, C. R. & Roth, J. Phlorizin: a review. Diabetes Metab. Res. Rev. 21, 31–38 (2005).
27. Sigillo, M., Brockhoff, A. & Meyerhof, W. Sweet-taste-suppressing colchicosides: current knowledge and perspectives of application. Appl. Microbiol. Biotechnol. 96, 619–630 (2012).
28. Sato, T. et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459, 262–265 (2009).
29. Fuji, M., Matano, M., Nanki, K. & Sato, T. Efficient genetic engineering of human intestinal enterocytes using electroporation. Nat. Protoc. 10, 1474–1485 (2015).
30. Pérez, C., Lucas, F. & Sclafani, A. Devazepide, a CCKA antagonist, attenuates sweet appetite. Cell Metab. 57, 99–112 (2016).
31. Fingar, T. E. ATP signaling is crucial for communication from taste buds to gustatory nerves. Science 310, 1495–1499 (2005).
32. Lu, V. B. et al. Adenosine triphosphate is co-secreted with glucagon-like peptide-1 to modulate intestinal enterocytes and afferent neurons. Nat. Commun. 10, 1029 (2019).
33. Tan, H. E. et al. The gut–brain axis mediates sugar preference. Nature 580, 51–56 (2020).
34. Boyden, E. S., Zhang, F., Bamberg, E., Nagel, G. & Deisseroth, K. Millisecond-timescale, genetically targeted optical control of neural activity. Nat. Neurosci. 8, 1263–1268 (2005).
35. Hibberd, T. J. et al. Optogenetic induction of colonic motility in mice. Gut 64, 2325–2336 (2015).
36. Kim, W. S. et al. Organ-specific, multimodal, wireless optoelectronics for high-throughput phenotyping of peripheral neural pathways. Nat. Commun. 12, 157 (2021).
37. Canales, A. et al. Multifunctional fibers for simultaneous optical, electrical and chemical interrogation of neural circuits in vivo. Nat. Biotechnol. 33, 277–284 (2015).
38. Park, S. et al. One-step optogenetics with multifunctional flexible polymer fibers. Nat. Neurosci. 20, 612–619 (2017).
39. Sapolsky, R. M. Behave: The Biology of Humans at Our Best and Worst. (Penguin Press, 2017).
40. Rolls, B. J., Rowe, E. A. & Rolls, E. T. How sensory properties of foods affect human feeding behavior. Physiol. Behav. 29, 409–417 (1982).
41. De Araujo, I. E., Schatzker, M. & Small, D. M. Rethinking food reward. Annu. Rev. Psychol. 71, 24.1–24.26 (2020).
42. Domingos, A. I. et al. Leptin regulates the reward value of nutrient. Nat. Neurosci. 14, 1562–1568 (2011).
43. Domingos, A. I. et al. Hypothalamic melanin concentrating hormone neurons communicate the nutrient value of sugar. *eLife* **2**, e01462 (2013).

44. Han, W. et al. A neural circuit for gut-induced reward. *Cell* **175**, 665–678 (2018).

45. Zhao, G. Q. et al. The receptors for mammalian sweet and umami taste. *Cell* **115**, 255–266 (2003).

46. Tellez, L. A. et al. Separate circuitries encode the hedonic and nutritional values of sugar. *Nat. Neurosci.* **19**, 465–470 (2016).

47. Drucker, D. B. & Sclafani, A. The role of gastric and postgastric sites in glucose-conditioned flavor preferences in rats. *Physiol. Behav.* **61**, 351–358 (1997).

48. Nathans, J., Thomas, D. & Hogness, D. Molecular genetics of human color vision: the genes encoding blue, green, and red pigments. *Science* **232**, 193–202 (1986).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022
Methods

**Mouse strains.** All experiments on mice were performed following approval by the Institutional Animal Care and Use Committee at Duke University Medical Center under protocol A280-18-12. Mice were group housed in Duke University's Division of Laboratory Animal Resources, where they were kept on a 12-h light/12-h dark cycle (7:00–19:00) with access to water and standard mouse chow (Purina 5001) ad libitum, unless otherwise indicated. The facility maintained an ambient temperature of 18–23 °C and humidity of 40–60%. Male and female adult mice aged 6–20 weeks were used in all experiments. In behavioral assays, animals of similar age and sex were used in experimental and control groups. Mouse strains, source, background and stock number used to breed experimental mice are listed below. The following experimental mouse strains were purchased, received or bred in-house and used directly: C57BL/6J (Jackson Laboratories, stock number 000664), Swiss Webster (Charles River Laboratories, stock number 00424) and CCK–GFP (courtesy of Dr. Rodger A. Liddle at Duke University, Swiss Webster background). The following transgenic double-transgenic strains were bred in-house: CckCRE_tdTomato, CckCRE_Halo-YFP, CckCRE_ChR2 and Neurod1CRE_Salsa6f. The following experimental mouse strains were purchased to breed the transgenic strains: CckCRE (Jackson Laboratories, C57BL/6J background, stock number 012567) and LSL_Salsa6f. The following experimental mouse strains were purchased, received or bred in-house and used directly: C57BL/6J (Jackson Laboratories, stock number 012706), Neurod1CRE (Jackson Laboratories, C57BL/6J background, stock number 028364), LSL_tdTomato (Jackson Laboratories, C57BL/6J background, stock number 007914), LSL_Halo-YFP (Jackson Laboratories, C57BL/6J background, stock number 014539), LSL_ChR2-tdTomato (Jackson Laboratories, C57BL/6J background, stock number 012567) and LSL_Salsa6f (Jackson Laboratories, C57BL/6J background, stock number 031968).

**Human duodenal samples.** Human duodenal samples were obtained from the Duke University Medical Center Biorepository and Precision Pathology Center under the Institutional Review Board protocol Pro00035974 via anonymous tissue release. Prior this protocol, informed consent was obtained from all study participants. All samples were deidentified, and all links to additional individual information were broken. Fresh surgical specimens. Following surgical extraction, samples were placed in sterile PBS and stored at 4 °C before cryopreservation.

**Vagus nerve recordings.** Whole-nerve electrophysiology recordings of the cervical vagus nerve were performed as previously reported. A 20-gauge gauze needle with two connected tubes for PBS perfusion and stimulant delivery was surgically inserted through the stomach wall into the duodenum or, for controls, the distal ileum (3 cm proximal to the cecum) or the proximal colon distal to the cecum. A perfusion exit incision was made at the ligament of Treitz for the small intestine or just proximal to the rectum for colon. PBS was constantly perfused through the isolated intestinal region at ~400 µl min⁻¹ as a within-subject baseline and volume pressure control. Stimulation conditions were applied after recording 2 min of baseline activity. During nutrient stimulation conditions, PBS perfusion was continuous, and 200 µl of stimulant was perfused over 1 min using a syringe pump (Fusion 200, Chemyx). The 1-min infusions of each ligand were separated by at least 6 min or the return to baseline perfusion of a preinhibitor response, one inhibitor was delivered over 1 min (devazepide and PPADS were delivered at 10 µl g⁻¹; the KA/AP3 cocktail was delivered at 20 µl g⁻¹). Inhibition of the stimulant ligand was repeated for 3–5 min for devazepide and 5–8 min for AP3 and PPADS.

**Data analysis.** Stimulus response was quantified as the maximum firing rate after stimulation (stimulant conditions) or during recording (baseline). Time to peak was also quantified as the time from the start of infusion to the maximum firing rate for stimulant conditions, which evoked vagal firing. Each trial served as its own control by normalizing the firing rate to the prestimulus baseline firing rate (first 2 min of recording). Maximum firing rate, time to peak and area under the curve were analyzed across stimulation condition.

**Dissociation and isolation of single intestinal epithelial cells.** Small intestines of mice were dissociated for single-cell RT-qPCR (CCK–GFP, N = 3 mice), calcium imaging (CckCRE_tdTomato; N = 8 mice) or in vitro electrophysiology (CckCRE_tdTomato; N = 9 mice) as previously described. Briefly, the proximal half of the ileum was mechanically dissociated with cold PBS and cut into sections. Tissue was shaken in 3 mM EDTA in PBS for 15 min at 4 °C followed by a 15-min incubation at 37 °C. The epithelium was then mechanically detached from the muscle by shaking in cold PBS. Following centrifugation at 800 r.p.m. (Eppendorf 5702 R; rotor A-4–38), the pellet was resuspended and incubated in HBSS with dispase and collagenase for 30 min at 37 °C. Samples were filtered (500 µM), filtered through 70- and 40-µM filters and resuspended in L15 medium (5% fetal bovine serum (FBS), 10 µl ml⁻¹ 10 mM HEPES, 2,000 U ml⁻¹ penicillin/streptomycin and 100 µl ml⁻¹ DNase) to produce a single-cell suspension for further analysis.

**CCK cell and vagal nodose neuron culture.** The small intestines of CckCRE_tdTomato mice were dissociated to single cells as described in Dissociation and isolation of single intestinal epithelial cells. Cells were sorted using fluorescence activated cell sorting (BD FACSAria) selecting for tdTomato⁺ neurons in medium were plated evenly on up to eight 150-mm dishes. Sorted cells were cultured in DMEM/F-12 medium (5% fetal bovine serum (FBS), 10 ng ml⁻¹ noggin and 100 ng ml⁻¹ R-spondin in Advanced DMEM/F-12). Sorted cells were plated on 2.5% Matrigel-coated (Corning, 356231) 12-mm coverslips at a concentration of ~5,000–10,000 enteroendocrine cells per coverslip. Nodose neurons were dissociated from C57BL/6J wild-type mice in the small intestine and cultured as described above. Calcium imaging of dissociated cells. Neurons in medium were plated evenly up to eight coverslips with or without enteroendocrine cells. Patch clamp electrophysiology was performed 2–3 d after plating.

**Patch clamp electrophysiology.** Enteroendocrine cells and nodose neurons were cocultured as described in the coculture section. Neurons alone were also cultured as described above onto coverslips. Coverslips were placed in the chamber filled with extracellular solution containing 140 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 2 mM MgCl₂ and 10 mM HEPES (pH 7.4, 300–300 mosM). CckCRE_tdTomato cells were identified by red fluorescence and neurons by their morphology and lack of fluorescence. Recordings were made using borosilicate glass pipettes pulled to ~3.5 MΩ resistance. For voltage clamp recordings, intracellular solution contained 140 mM CsF, 10 mM NaCl, 0.1 mM CaCl₂, 2 mM MgCl₂, 1 mM EGTA, 10 mM HEPES and 10 mM sucrose (pH 7.25, 295 mosmol). Neurons were held at ~50 mV for 2 min after patching in voltage clamp mode to stabilize membrane. Membrane time constant, cell capacitance and voltage threshold were determined using 200-millisecond steps from ~70 mV to +20 mV in 10-mV increments. Calcium imaging of dissociated cells. Neurons in medium were plated evenly up to eight coverslips with or without enteroendocrine cells. Calcium imaging of dissociated cells.
above was run before and after each stimulus application to ensure neuron health. Neurons that did not respond to voltage step were not included in the analysis.

**Data acquisition.** Recordings were performed at room temperature using a MultiClamp 700B amplifier (Axon Instruments), digitized using a Digidata 1500A (Axon Instruments) interface and visualized in pClamp software (Axon Instruments). Data were filtered at 1 kHz and sampled at 10 kHz.

**Data analysis.** Cell capacitance was calculated as $C_{in} = (r \times L)/\Delta F$, where $r$ is the time constant of the decaying transient current, $\Delta F$ is the voltage step and $L$ is the current transient relative to prepulse potential (Platzer, 2016, 123). To account for cell variability and health, max current was normalized to the cell capacitance. Data are presented as the mean ± s.e.m. in log scale. Significance was determined using a two-tailed Student’s t-test with $n = 0.05$.

**Calcium imaging of dissociated cells.** For neurons, C57BL/6J (N = 3 mice) nodose neurons were dissociated and plated as previously described. Briefly, nodose ganglia were dissected and immediately placed into 500 μl of ganglia dissociation solution containing 10 mM HEPES, 1 mM GlutaMax, 1 mM N2 supplement, 1 mM B27 supplement, 0.5 μg/ml 1 μM NGF and 55 μg/ml 1 μM Liberase (Roche, 5401054001) in Advanced DMEM/F-12. Following digestion, ganglia were rinsed twice with PBS, mechanically dissociated in dissociation solution and filtered through a 70-μm cell strainer. The cells were then plated on 12-mm coverslips and placed in a 37 °C incubator overnight. Cells were imaged 1–2 d after plating. Amacrine and ganglion cells were dissociated as described in Dissociation and isolation of single intestinal epithelial cells and fluorescence sorted (BD FACSAria) selecting for tdTomato+ fluorescent cells. Cells were then plated on coverslips coated with 2.5% Matrigel (Corning, 353210). Enterendocrine cells were imaged 2–6 h after plating. To load cells with calcium dye, cells were washed once with calcium-free PBS and incubated for 45 min with 1 μM Fluo-4 AM and 5 μM Fura Red AM. Calcium dyes (Life Technologies) and 0.1% Pluronic F-127 (Life Technologies) in imaging buffer (120 mM NaCl, 3 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM HEPES, 10 mM glucose; 305 mosM) were loaded into the recording chamber of a Zeiss Examiner Z1 and imaged with a Hamamatsu camera (Orca-flash4.0, C11440) using the Zen software package. Fluo-4 and Fura Red emission images were obtained using 488- and 570-nm excitation, respectively. Images were collected at 1.5-s intervals with a 100-ms exposure time. Each recording was 210 s (3.5 min) long. Imaging buffer was continuously perfused (~2 ml/min) over the coverslips throughout the imaging session. Two stimuli were applied during each recording, 20 mM KCl and 2 mM sucrose. Stimuli were delivered for 15 s with 30 s of buffer perfused in between each stimulus. The order of the experimental stimuli was alternated to offset potential order effects. Each recording session concluded with 50 mM KC1 as an activity control (KC1 concentration was achieved by substituting for NaCl and not an addition of more KC1). A response to KC1 was defined as a ratio increase >10% above baseline. Cells that did not reach this KC1 threshold were not included in the analyses.

**Analysis.** Fluorescence values for each individual cell were calculated as the mean fluorescence intensity in a user-defined region of interest in Fiji software. Intracellular calcium changes were then calculated as $\Delta F/\Delta F_{o} = (F - F_{o})/F_{o}$, where $F$ is the mean fluorescence intensity of entire run)/average $F$ of entire run. Stimulus response was quantified as the maximum $\Delta F/\Delta F_{o}$ after stimulation onset. A positive response was defined as an increase of >20% over baseline within each neuron.

**Single-cell RNA sequencing.** Left (N = 6) and right (N = 5) nodose ganglia from adult C57BL/6J wild-type euthanized mice were dissected as described in Calcium imaging of dissociated cells and separated into two distinct tubes. Dissections were completed in tandem by three lab members, and all nodose ganglia were dissected within 15 min, at which point 55 μg/ml Liberase (Roche) was added to each tube. Ganglia were dissociated into single cells as described in the coculture section. The dissociated solution was then carefully laid on a density gradient of 500 μl of ganglia dissociation solution containing 10 mM HEPES, 1 mM GlutaMax, 1 mM N2 supplement, 1 mM B27 supplement, 0.5 μg/ml 1 μM NGF and 55 μg/ml 1 μM Liberase (Roche, 5401054001) in Advanced DMEM/F-12. Following digestion, ganglia were rinsed twice with PBS, mechanically dissociated in dissociation solution and filtered through a 70-μm cell strainer. The cells were then plated on 12-mm coverslips and placed in a 37 °C incubator overnight. Cells were imaged 1–2 d after plating. Amacrine and ganglion cells were dissociated as described in Dissociation and isolation of single intestinal epithelial cells and fluorescence sorted (BD FACSAria) selecting for tdTomato+ fluorescent cells. Cells were then plated on coverslips coated with 2.5% Matrigel (Corning, 353210). Enterendocrine cells were imaged 2–6 h after plating. To load cells with calcium dye, cells were washed once with calcium-free PBS and incubated for 45 min with 1 μM Fluo-4 AM and 5 μM Fura Red AM. Calcium dyes (Life Technologies) and 0.1% Pluronic F-127 (Life Technologies) in imaging buffer (120 mM NaCl, 3 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM HEPES, 10 mM glucose; 305 mosM) were loaded into the recording chamber of a Zeiss Examiner Z1 and imaged with a Hamamatsu camera (Orca-flash4.0, C11440) using the Zen software package. Fluo-4 and Fura Red emission images were obtained using 488- and 570-nm excitation, respectively. Images were collected at 1.5-s intervals with a 100-ms exposure time. Each recording was 210 s (3.5 min) long. Imaging buffer was continuously perfused (~2 ml/min) over the coverslips throughout the imaging session. Two stimuli were applied during each recording, 20 mM KCl and 2 mM sucrose. Stimuli were delivered for 15 s with 30 s of buffer perfused in between each stimulus. The order of the experimental stimuli was alternated to offset potential order effects. Each recording session concluded with 50 mM KC1 as an activity control (KC1 concentration was achieved by substituting for NaCl and not an addition of more KC1). A response to KC1 was defined as a ratio increase >10% above baseline. Cells that did not reach this KC1 threshold were not included in the analyses.

**Analysis of nodose single-cell sequencing data.** RT-PCR was performed on the sequence version of the snapShot cDNA synthesis kit. For all single-cell assays, quality control was performed using Chromium Single-Cell 3′ v2 RT-PCR kit according to the manufacturer’s guidelines. Libraries were sequenced on an Illumina NextSeq 500. The Cell Ranger pipeline version 2.1.1 was used with the mm10 mouse reference genome version 2.1.0 to convert raw data to fast format and align, map and count genes.

**Single-cell RT-qPCR.** RNA isolation from single cells was performed using the Direct One-Step qRT-PCR kit (CDK kit, Thermo Fisher) per the manufacturer’s protocol. Lysis Buffer Mix (5 μl) was pipetted into each well of a 96-well plate and centrifuged at 500g to spread buffer. Following the dissociation protocol, single cells were sorted into a U-bottom 96-well plate (Sigma) based on GFP signal using a MoFlo XDP sort. For each mouse, 60 GFP+ cells, 30 GFP cells and control wells were sorted. Control wells of 0, 10 and 100 cells were run in duplicate. Following sorting, the contents of each well were pipetted into a 96-tube, 0.2 ml PCR plate, which was then incubated in a thermocycler at 75 °C for 10 min. After centrifuging to pellet, DNase I reaction buffer from the CDK kit was added to each well and incubated at 25 °C for 5 min. Two microliters of 25 mM EDTA was added to each well, vortexed and pelleted. The plate was then incubated at 75 °C for 10 min to inactivate DNase I. Next, CDNA was synthesized and amplified. Specific Target Amplification (STA) mix was made by mixing 1 μl of each TaqMan probe. STA mix, superscript reverse transcriptase (RT) and reaction buffer from the CDK kit were added to each sample and incubated on a thermocycler for 15 min at 50 °C, 2 min at 95 °C and 20 cycles of 15 s at 95 °C and 4 min at 60 °C. Gene expression was then probed using the 96.96 Dynamic Array integrated fluidic circuit on a Biomark using the manufacturer’s protocol (Fluidigm).

**Quality control.** Quality of the threshold cycle (C) values from the Biomark output was assessed using the Fluidigm Real-Time PCR Analysis software (Fluidigm). All trials (N = 3 mice; n = 60 positive cells and 30 negative cells per mouse) were loaded. The quality was analyzed in linear derivative mode, and the quality threshold was set at 0.65 based on the manufacturer’s recommendations. All curves not meeting the quality threshold were analyzed visually for smoothness (more smooth representing high quality) and entered into analysis based on comparison with passing curves. All cells not meeting quality measures or having no detected transcripts for either housekeeping gene (Gapdh) were discarded for 60 s with 2 min of baseline before and after application.

**Data analysis.** Fluorescence values for each individual neuron were calculated as the mean fluorescence intensity in a user-defined region of interest using Fiji software. Intracellular calcium responses were calculated as $\Delta F/F_{o} = (F - F_{o})/F_{o}$, where $F$ is the mean fluorescence intensity of entire run)/average $F$ of entire run. Stimulus response was quantified as the maximum $\Delta F/F_{o}$ after stimulation onset. A positive response was defined as an increase of >20% over baseline within each neuron.
Articles

or Actb) were excluded from analysis (48 positive cells and 24 negative cells were excluded).

Analysis. Further processing of C values was performed based on Stähberg et al. Relative quantities (RQ) of cDNA molecules were calculated using the formula \( RQ = 2^{(-\Delta \Delta C)} \) using a Q<sub>eq</sub>uant Value of 34. The RQ value for any sample expressing no detectable transcripts for a gene was set at 0.5. All data were expressed in a log<sub>2</sub> scale. Heat maps were generated for gene expression normalized within each gene (mean of 0; s.d. of 1) using Quocore Omics Explorer (Quocore). Differential gene expression analysis ((1) CCK–GFP versus CCK–GFP, (2) Slc5a1<sup>−/−</sup> versus Slc5a1<sup>−/−</sup> in CCK–GFP<sup>+</sup> cells and (3) Tais1<sup>−/−</sup> versus Tais1<sup>−/−</sup> from CCK–GFP<sup>+</sup> cells) was performed using two-tailed group t-test comparisons with a q value cutoff of 0.05 (as implemented by Qucomere).

Immunohistochemistry. CCK–GFP (N = 3) mice were transcardially perfused with PBS for 3 min followed by 4% paraformaldehyde (PFA) for 3 min at a rate of 600 µl min<sup>−1</sup>. Each small intestine was collected, opened lengthwise, rolled with the proximal end in the center and postfixed in 4% PFA for 3 h. Tissue was then dehydrated in 10% sucrose for 24 h and 30% sucrose for 24 h each. Samples were embedded in optimal cutting temperature (OCT) (VWR) and stored at −80 °C. Tissue was sectioned onto slides at 14 µm using a cryostat. Tissue slides were postfixed in 10% normal buffered formalin (VWR) for 10 min and wicked in Tris-buffered saline with 0.05% Tween-20 (TBST) (Sigma). SGLT1 staining were postfixed in 10% normal buffered formalin (VWR) for 10 min and washed at 80 °C. Tissue was sectioned onto slides at 14 µm using a cryostat. Tissue slides were postfixed in 10% normal buffered formalin (VWR) for 10 min and washed in Tris-buffered saline with 0.05% Tween-20 (TBST) (Sigma). SGLT1 staining was achieved by performing heat-mediated antigen retrieval. Trisodium citrate dihydrate buffer (10 mM in PBS, 0.05% Tween, pH 6.0; Sigma) was heated in a microwave to 600°C. Tissue slides were then immediately placed into cool tap water and washed in TBST for 5 min. Tissue was blocked in 10% donkey serum (Jackson Immunomutation Research) for 1 h. Tissue was then incubated with primary antibody dissolved in antibody dilution solution (PBS with 1% BSA and 0.0025% Triton-X 100) for 24 h at 4 °C and then 1 h at room temperature. The following primary antibodies were used: anti-SGLT1 (rabbit, Abcam, ab16686; 1:100) and anti-GFP (chicken, Abcam, ab13970; 1:500). After primary antibody incubation, tissue was washed in TBST and incubated with secondary antibody in antibody dilution solution (1:250) for 1 h at room temperature. The following secondary antibodies were used: Alexa Fluor 488 AffiniPure F(ab')2 Fragment Donkey Anti-Rabbit IgG (H+L) (Jackson Immunomutation Research, 711-546-152; RRID:AB_2340376). Tissue was then washed with TBST, stained with DAPI (1:4,000) for 3 min, washed in TBST and mounted using Fluoro-Gel with Tris Buffer (Electron Microscopy Sciences). Imaging was done on a Zeiss 880 Airyscan inverted confocal microscope. Images were adjusted for brightness/contrast using ImageJ (Fiji).

In situ hybridization. CCK–GFP (N = 3) mice were transcardially perfused with PBS for 3 min followed by 4% PFA for 3 min at a rate of 600 µl min<sup>−1</sup>. Each small intestine was collected, opened lengthwise, rolled with the proximal end in the center and postfixed in 4% PFA for 24 h. Tissue was then dehydrated in 10% sucrose and 30% sucrose for 24 h each. Samples were embedded in OCT (VWR) and stored at −80 °C. Tissue was then washed in PBS until clear and incubated in 5 mM EDTA in PBS for 15 min. Crypts were detached by shaking in cold PBS, pelleted at 100 g and resuspended in Matrigel (Corning, 356231). Crypts were plated in 50-µl mounds in 24-well plates and maintained in Human Intesti mum (Cell, 06010) with 10 µg M 07632 at initial plating.

Glutamate release assay. Murine or human small intestinal organoids were passaged and plated into a 96-well plate in 25 µl Matrigel mounds in organoid culture medium as above. The human organoid medium contained 500 ng ml<sup>−1</sup> human R-spondin (Peprotech) and was supplemented with 500 nM A-83-01 (Tocris) and 10 nM leu-gastrin (Sigma) for differentiation for 10 µM Y 07632 at passage<sup>1</sup>. When mature morphology was achieved 3–7 days after passage, medium was removed, and organoids were washed in PBS twice for 5 min at room temperature. Organoids were then stimulated with 60 µl of 300 µM sucrose, 150 mM α-MGP, 15 µM sucalrose or PBS for 10 min at 37 °C. Supernatant was collected, centrifuged for 10 min at 13,000 g to remove insoluble material and stored at −20 °C for up to 2 weeks. Glutamate concentration in samples was assessed using the Glutamate Release Assay kit (Sigma). Fifty microliters of each sample was mixed with buffer, glutamate enzyme mix and developer following the manufacturer’s protocol. Each experimental condition was run in triplicate on every plate. A glutamate standard was run for every plate. Control wells of sample were developed with a known amount and run in triplicate for each sample. Absorbance at 450 nm was measured on a plate reader (Tecan Infinite 200 Pro). Nine reads were taken per well and averaged. The absorbance from the control was subtracted from each experimental sample absorbance for the corrected value. Glutamate amount and concentration was calculated using the standard curve.

Flexible fiberoptic implant fabrication. Waveguide fabrication. The step index core/cladding flexible polymer waveguide was fabricated using the thermal drawing process starting from a macroscopic polymer preform (template)<sup>29,30</sup>. The preform was assembled by inserting a PC rod (1/8” (3.81 cm) in diameter, McMaster-Carr) into a PMMA tube (1/4” (7.62 cm) outer diameter and 9/32” (3.81 cm) inner diameter; US Plastics) and then consolidating the rod-in-tube assembly at 170 °C in a vacuum oven. The resulting preform was drawn into a meters-long fiber in a custom-built fiber drawing tower at a temperature of 270 °C. The lateral dimensions of the preform were reduced by 30 times to produce a microfiber (220- to 230-µm-diameter) PC/PMMA core/cladding optical waveguide.

Physical characterization of flexible polymer waveguide. Optical transmission loss of the fiber was quantified by coupling the fibers to a diode-pumped solid state laser (Laser Quantum XLS-150-10M, 802 nm). A glass fiber with Fluoroptic MM-2550 µm output, wavelength λ = 473 nm) via ferrules, and the light output was measured by a photodetector (S121C, 400–1,100 nm, 500 mW; Thorlabs) attached to a power meter (PM100D, Thorlabs). Optical transmission was quantified for a range of fiber lengths (1–10 cm), bending angles (0°, 90°, 180° and 270°) and radii of curvature (0.5, 1, 2.5, 7.5, 10, 12.5 and 15 mm).

Gut implant fabrication. To optically couple as-drawn fibers to a light source, 9- to 10-µm-long fibers were inserted into a 10.5-mm-long, 2.5-mm-diameter, 231-µm bore size ferrule (Thorlabs) and affixed with optical epoxy (Thorlabs). The ferrule edge was then polished using a Thorlabs fiber polishing kit. Fiber was then threaded through ~7.5 cm of microrenathane tubing (BrainTree Scientific) to create an intraluminal stent and 270°). The proximal tubing closest to the ferrule was opacified with liquid electrical tape (Starbrite) to reduce non-specific activation of CCK-expressing cells in the skin (Fig. 5f). The final length of the device was ~9.25 cm including the ferrule; ~1.5 cm of the device could be illuminated and ~0.75 cm of fiber extended beyond the tubing. The average power recorded from the device tip was measured using a photodetector (S140C, 250–1100 nm, 500 mW; Thorlabs) attached to a power meter (PM100D, Thorlabs). Average power output (optical intensity) at the end of the PC/PMMA fiber with a 5-40, Hz–532 nm laser input was 1.07 mW mm<sup>−2</sup> before implantation.

Gut fiberoptic implantation surgery. Adult CckCRE_Halo-YFP, Halo-YFP, CckCRE, ChR2 mice or littermates were singly housed and acclimated to behavioral cages (TSE PhenoMaster) 1 week before surgery. Mice were anesthetized with isoflurane (1–3% in oxygen). A 2-cm incision was made from the xiphoid process diagonally to the left-mid clavicular line. The peritoneal cavity was accessed, and the stomach was extracorporealized for implantation. A purse string suture was made in the gastric antrum, avoiding blood vessels. A small incision was made in the

NATURE NEUROSCIENCE | www.nature.com/natureneuroscience
stomach within the suture, and a gavage needle was used to dilate the pylorus. The distal end of the device was threaded into the proximal duodenum so that the illuminated region of the device was in the proximal small intestine (Fig. 5h). The purse-string placed to secure the device in the intestine. A portion of the device was tunneled to the base of the skull. The peritoneum and overlying skin were sutured. The device exited the tunnel at the base of the skull and was skull mounted; skull mounting was required to maximize longevity of the implant. For maximal adhesion, the skull was etched with a razor blade, and a thin layer of Metabond cement (Clear L-Powder S399-catalyst; Metabond) was applied. Then, the Metabond layer was etched and the device attached using standard dental cement (Stoelting, 51458). Mice recovered for at least 5 d or until normal feeding behavior and activity returned.

**Fiber durability.** For all experiments using the flexible fiberoptic device, a total of 40 mice were implanted for experimentation. Of the 40 mice implanted, 36 had devices that were intact and functional (90% success rate). Failure was due to a break in the tip of the fiber where it exits the tubing (four total devices). Data from mice with broken fiberoptic devices were excluded from analyses.

**Duodenal catheter surgery.** Adult C57BL/6j wild-type mice were surgically implanted with catheters into the duodenum, using a similar procedure as previously described9,64. Mice were anesthetized with isoflurane (1–3% in oxygen). A 2-cm incision was made from the xiphoid process diagonally to the left-mid clavicular line. The peritoneal cavity was accessed and the stomach extracorporealized for catheter implantation. Microrenathane tubing (BrainTree Scientific) with one silicone ball (Home Depot) at implantation end, was inserted into a small incision made in the stomach within a purse string suture. The distal end of the catheter was threaded into the proximal duodenum, and the silicone ball was sutured inside the stomach to keep the catheter in place. The other end of the catheter was tunneled to the back and directed out in the small intrascapular incision. This end was sewn in place with surgical mesh. The proximal end of the catheter was sealed with a metal cap. Mice were then singly housed and recovered for at least 5 d until normal feeding behavior and activity returned.

**Phenotyping equipment.** All optogenetic behavior experiments were performed in a principal investigator-managed husbandry system. Animals were housed in a custom-built Phenomaster behavioral phenotyping system (TSE Systems). The Phenomaster was programmed (software version 6.6.9) to automatically maintain a light cycle (7:00 lights on; 19:00 lights off), temperature control (22°C) and humidity control (40%). The Phenomaster holds 12 clear cages in which animals were singly housed. Cages were industrially washed and bedding (ALPHA-dri) was replaced weekly. Animals were provided with standard mouse chow (Purina 5001) and reverse osmosis water ad libitum unless fasted for a choice assay. All cages housed an enrichment device, which also served to weigh the animals. A food hopper, water bottle and weigh container were attached to weight sensors (TSE). Food intake, water intake and weight were automatically measured every 5 s to the nearest 0.01 g. For drinking measurements, a 10-s smoothing interval with a maximum raw analog-to-digital conversion counts difference of 40,000 was permitted. For weight measurements, a 15-s smoothing interval with a 15-g threshold and a maximum raw analog-to-digital conversion counts difference of 1,000,000 was permitted. Intake was measured every 5 s and binned every 1 min for analyses, unless otherwise indicated. Animal activity was determined by beams crossed in the x and y planes and was collected with a 100-Hz scan rate. For optogenetic stimulation experiments, custom PhenoMaster software drove scheduled TTL pulses, which triggered laser on/off. For optogenetic experiments, TTL signals were set to be triggered every 3 min. Each cycle included 1 min on with a 40-Hz, 5-V pulse at 20% duty cycle and 2 min off. Each experimental session with laser stimulation began with 1 min of laser on. Following experiments, raw data were downloaded from the Phenomaster software and analyzed using MATLAB software (MathWorks). Unless otherwise indicated, all activity, food intake and water intake measurements were binned in 1-min intervals for analysis. Data were corrected for minor fluctuations by only permitting a monotonically increasing function for both food and water intake; values that represented negative food intake were replaced by the most recent value.

**Plexiglass cage manufacturing.** The choice assay paired with intraduodenal drug delivery occurred in in-house-manufactured clear plexiglass cages. Clear plexiglass cages were individually housed in the Phenomaster. Following recovery, mice were habituated to gavage, handling and connection to the fiber patch cable. On experimental days, mice were gavaged with a fat solution (7% Intralipid diluted in PBS, Sigma) or PBS (delivered as 0.1 ml per 10 g) after 90 min of food and water restriction. Immediately following gavage, mice received inhibiting (532-nm) or control (473-nm) light stimulation (40 Hz, 5 V, 20% duty cycle). Thirty minutes after gavage, food and water was available for 3 h, during which the light stimulation continued. Food intake was continuously measured for 3 h. Food intake was calculated as gram of chow intake per gram body weight.

**Oral glucose tolerance test.** Blood glucose was measured in adult CckCRE_Halo mice (N = 4) by an oral glucose tolerance test. Mice were food and water deprived for 1 h. Then, mice were gavaged with sucrose (1 M, as 0.1 ml g–1 mouse; approximate sucrose concentration consumed in 1-h choice assay) and received 10 min of 532-nm or 473-nm light stimulation (40 Hz, 5 V, 20% duty cycle). Blood glucose was measured (True Metrix 60 Blood Glucose Meter) after 1 h of deprivation (10 min), immediately following gavage (0 min) and after 10 min of laser inhibition (10 min).

**Total gut transit time.** Total gut transit time was performed as previously described. Adult CckCRE_Halo mice (N = 4) were implanted with a flexible fiberoptic. Following recovery, mice were habituated to gavage, handling and connection to the fiber patch cable. On test days, mice were food and water restricted for 1 h. Then, mice received a gavage of a solution containing Evans Blue (5%; Sigma) and methylcellulose (0.5%; Sigma) mixed in 300 mM sucrose in 1 X PBS (pH 7.4) to mark the pylorus (532-nm light) or control (40 Hz, 5 V, 20% duty cycle). Bleeding was evaluated for a blue fecal pellet every 10 min. Total gut transit time was calculated as the time between the gavage and the first blue fecal pellet. At euthanasia, one device was broken, and data from that mouse were excluded from analysis.

**Gallbladder emptying.** Gallbladder emptying, an effect of CCK, was measured by calculating gallbladder volume before and after stimulation perfusion to the duodenum. Serum levels of CCK were not measured due to the unreliability of commercial kits. Gallbladder volume was calculated using previously published reports65,66. Wild-type mice were fasted overnight before being fully anesthetized under isoflurane. A laparotomy was performed, and the gallbladder was gently exposed and measured using a microcaliper. Gallbladder volume was calculated using the formula gallbladder volume (μl) = length (mm) x width (mm) x depth (mm) x 6/π (ref. 67). A gallbladder needle was inserted and secured in the duodenum through the pylorus and was connected to an infusion pump (TSE Systems). Mice received an infusion of PBS (negative control), corn oil (positive control; Canola) or sucrose (300 mM) at 40 Hz (postweight/preweight) x 100. A separate cohort of CckCRE_Halo mice were implanted with flexible fiberoptic devices in the duodenum. Mice were fasted overnight before receiving a gavage of PBS (control), corn oil (positive control; Canola) or sucrose (300 mM). Fifteen minutes later, mice were killed, and the duodenum and esophagus were clamped and tied off securely with suture thread. The stomach was then removed and weighed. The stomachs were desiccated at 65°C for 6 d before being weighed again. Gastric emptying was calculated as gastric emptying (% volume remaining) = (postweight/preweight x 100). A separate cohort of CckCRE_Halo mice were implanted with flexible fiberoptic devices in the duodenum. Mice were food and water deprived for 1 h. They were then gavaged with PBS or sucrose (300 mM) and received laser stimulation (40 Hz, 5 V, 20% duty cycle) for 15 min, and stomachs were dissected as described above.

**Choice assay.** Mice were given free access to 300 mM sucrose and 15 mM saccharose for 24 h in the home cage to control for neophobia. During 24-h access, mice had ad libitum access to food and water, although water intake was negligible; implanted mice were not connected to patch cables. For each subsequent choice assay, at the start of the dark cycle (19:00), mice were placed in a cage with fresh bedding and restricted of food and water either in the Phenomaster or plexiglass cages. One hour after onset of the dark cycle (20:00), 300 mM sucrose and 15 mM saccharose became available for free consumption for 1 h. Concentrations were selected based on prior studies showing iso-sweetness68,69. The side of the sucrose and saccharose solutions was swapped each test to control for side preferences. To advance to optogenetic or pharmacologic inhibition, mice were required to display a clear preference for sucrose, defined as >66% sucrose preference in two consecutive tests and not varying by more than 15% across both tests. For five mice who did not display a clear preference by the seventh test or displayed a clear side preference by the third test were reexposed for 24 h as above. The average number of test days to advance to optogenetic or intraduodenal infusion tests was 5-6 days. Following appropriate (optogenetic and intraduodenal infusion tests) and given ad libitum access to food and water. The start of all test sessions was separated by at least 48 h.

**Optogenetic inhibition.** Implanted CckCRE_Halo-YFP mice (final N = 8, N = 5 male/3 female) and their wild-type littermates (final N = 5, N = 3 male/2 female)
underwent baseline choice assays as described in Choice assay. Testing occurred in our TSE PhenoMaster apparatus. During all baseline and experimental assays, mice were connected to the laser using a custom swivel arm (TSE) coupled to a rotary joint patch cable (Thorlabs, RFP23) for free movement at any time of day with no conflict due to a strong side preference. Thirty minutes before the onset of the dark cycle, food and water was removed. Mice received an injection of a cocktail of glutamate receptor antagonists (150 μg kg⁻¹ KA and 1 mg kg⁻¹ AP3, intraperitoneally) 25 min before access to sucrose, which coincided with the onset of the dark cycle. Mice had access to sucrose (15 mM) for 1 h.

Statistics and reproducibility. We performed statistical analyses using JMP Pro Software (version 14, SAS), unless otherwise indicated. Data were evaluated for normality using the Q-Q plot. For normally distributed data, an ANOVA was used, and a Tukey's honestly significant different post hoc testing was performed when applicable. For behavior studies, we used a repeated measures ANOVA to account for each subject and follow with post hoc paired Student's t-tests. For data not normally distributed, means were evaluated by a Kruskal–Wallis test with non-parametric comparisons using the Wilcoxon method. For other studies, comparison of statistical tests performed are included throughout the Methods and in figure legends. All error bars and shaded regions represent s.e.m. unless otherwise indicated. Sample size was not predetermined using power analyses. No statistical methods were used to predetermine sample sizes, but our sample sizes are similar to those reported in previous publications. Standardized randomization was not performed for in vitro or in vivo experiments. All behavioral studies were counterbalanced across age and sex to control for variables including position in cage, order effect and handedness. Data collection and analysis were not performed blind to the conditions of the experiments.

Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability
The source data that support the findings of this study are available from the corresponding author upon request. The mm10 mouse reference genome is available from GENCODE vM32/Ensembl 98. Single-cell sequencing data sets are available on the NIH Gene Expression Omnibus database (GSE185173).

Code availability
All custom code used for analysis in this paper is available from the corresponding author upon request.

References

| Author(s) | Title | Journal | Year |
|-----------|-------|---------|------|
| Wang, Y. et al. | Amino acids stimulate cholecystokinin release through the CCK-α-sensing receptor. | Am. J. Physiol. Liver Physiol. | 2010 |
| Zhang, L. et al. | CCK-A and CCK-B receptors mediate antinociception and proalgesic effects in the mouse spinal cord. | J. Neurosci. | 2013 |

NATURE NEUROSCIENCE | www.nature.com/natureneuroscience

Methods

One bottle assay. CckCRE_Chr2 mice (final N = 4; CckCRE_Chr2, N = 2 male/2 female; N = 4 littermate controls, N = 2 male/2 female) were acclimated to the PhenoMaster and implanted with flexible fiberoptic implants as described above (Gut fiberoptic implantation surgery). Implanted mice were given free access to sucrose (15 mM) 24 h before the home cage to control for neophobia. During 24-h access, mice had ad libitum access to food and water, although water intake was negligible; implanted mice were not connected to patch cables during exposure. For each one-bottle assay, 5 min before the start of the dark cycle, access to food and water was closed, and mice were attached to the rotary joint patch cable (Thorlabs, RFP23) for free movement in mice. Mice remained in the home cage. At the start of the dark cycle, sucrose (15 mM) became available for free consumption for 1 h. Following each test session, mice were disconnected and given ad libitum access to food and water. The start of all test sessions was separated by at least 48 h. Each mouse underwent two habituation conditions (sucrose (15 mM), no laser) followed by two experimental conditions: sucrose + 473 nm (activating) and sucrose + 532 nm (control). The order of experimental conditions was randomized across mice. During photostimulation conditions, the Phenomaster delivered a TTL pulse for laser stimulation based on intake as follows: for every 0.01 g of liquid consumed, the mice received 5 s of laser stimulation (532 nm, 20% duty cycle). Fiberoptic placement and power output was confirmed at the end of the surgery. Only mice that completed all tests and whose device had appropriate power/placement were included in the analysis. One mouse was excluded from the analysis due to a broken fiber in the lumen.

Pharmacological blockade. The test above was repeated in a separate group of CckCRE_Chr2 mice (N = 3; N = 1 male/2 female) with a slight modification.

This article is protected by copyright. All rights reserved.
65. Wei, L. et al. Serotonin deficiency is associated with delayed gastric emptying. *Gastroenterology* **160**, 2451–2466 (2021).

66. Shahid, R. A. et al. Endogenous elevation of plasma cholecystokinin does not prevent gallstones. *Eur. J. Clin. Invest.* **45**, 237–246 (2015).

67. Everson, G. T., Braverman, D. Z., Johnson, M. L. & Kern, F. J. A critical evaluation of real-time ultrasonography for the study of gallbladder volume and contraction. *Gastroenterology* **79**, 40–46 (1980).

68. Ferreira, J. G., Tellez, L. A., Ren, X., Yeckel, C. W. & de Araujo, I. E. Regulation of fat intake in the absence of flavor signalling. *J. Physiol.* **590**, 953–972 (2012).

69. Almeida, R. L. et al. Inhibition of sodium appetite by lipopolysaccharide: involvement of α2-adrenoceptors. *Am. J. Physiol. Regul.* **301**, R185–R192 (2011).

**Acknowledgements**

The original version of this manuscript was first deposited on bioRxiv on 8 March 2020. The authors thank S. Simon, R. Liddle, L. Saraiva, E. Bohórquez, P. Weng, M. Montoya Gomez, B. Barth, B. Florentino and E. Freed for their feedback and contributions, D. Niedzwiecki for statistical consultation, C. Anderson and G. Kelly in the CGIBD Advanced Analytics Core for assistance in single-cell qPCR experiments and staff of the Duke Light Microscopy Core, Flow Cytometry Core and Division of Laboratory Animal Resources. This work would not have been possible without the use of mice as a model. This work was funded by an HHMI Medical Research fellowship to K.L.B., F32 DK127757 and a Hartwell Postdoctoral Fellowship to L.E.R., T32 DK007568 to M.M.K., an L. H. McGovern fellowship to A.S., F30 DK122712 to WWL., a Tan-Yang grant to P.A. and a Duke NUS Pilot Research Grant, R21 AT010818, DP2 MH122402 and R01 DK131112 to D.V.B.

**Author contributions**

K.L.B. optimized and performed flexible fiber implantation surgery and behavior experiments and performed vagal cuff recordings, single-cell qPCR experiments, optogenetic behavioral studies and associated data analysis. L.E.R. optimized and performed pharmacologic behavior experiments, optogenetic behavior studies, gastric emptying, oral glucose tolerance test (OGTT), vagal cuff recordings and feeding studies. M.M.K. performed all single-cell calcium imaging, coculture patch clamp electrophysiology experiments, in vivo calcium imaging and associated data analysis. A.S., S.P. and P.A. designed and fabricated the flexible fiberoptic. M.E.K. cultured and maintained all organoids. M.E.K., K.L.B. and A.Y. optimized and performed glutamate release assays. K.L.B. and WWL. optimized the behavioral phenotyping system. WWL. analyzed single-cell RNA sequencing data and performed in situ hybridization experiments and vagal cuff recordings. J.A.V. planned and performed all animal breeding, mouse colony management, genotyping and quality control. J.G. performed immunohistochemistry experiments. K.L.B., L.E.R., M.M.K. and D.V.B. planned experiments and composed figures. D.V.B. conceptualized the project, supervised the research and wrote the final manuscript.

**Competing interests**

Some of the findings have been filed by D.V.B. as a provisional patent application (MBF reference number 028193-9344-US01). All other authors declare no competing interests.

**Additional information**

Extended data is available for this paper at https://doi.org/10.1038/s41593-021-00982-7. Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41593-021-00982-7. Correspondence and requests for materials should be addressed to Diego V. Bohórquez.

**Peer review information** *Nature Neuroscience* thanks Carlos Campos, Tony Lam and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

**Reprints and permissions information** is available at www.nature.com/reprints.
Extended Data Fig. 1 | Vagal responses to sugars, sugar analogs, and sweeteners are not due to osmolarity and are specific to the small intestine, related to Fig. 1. a, Normalized maximum vagal firing rate to baseline (PBS), sugars (sucrose [300 mM] (N = 10), D-glucose [150 mM] (N = 5), D-fructose [150 mM] (N = 5), D-galactose [150 mM] (N = 5)), sugar analogs (alpha-methylglucopyranoside (α-MGP) [150 mM] (N = 8)), and maltodextrin [8%] (N = 5)), and sweeteners (sucralose [15 mM] (N = 11), acesulfame K (ace-K) [15 mM] (N = 5), and saccharin [30 mM] (N = 5)). *p < 0.009 by Kruskal-Wallis test with non-parametric comparisons using Wilcoxon Method. P-values comparing baseline to each stimulus: sucrose, p < 0.0001; D-glucose, p = 0.0004; D-fructose, p = 0.6868; D-galactose, p = 0.0004; α-MGP, p < 0.0001; maltodextrin, p = 0.0005; sucralse, p < 0.0001; ace-K, p = 0.0005; saccharin, p = 0.0008. b, Time-to-peak vagal firing rate for sugar stimuli (N as in a; n.s.). c, Normalized maximum vagal firing rate to intraduodenal sucrose [300 mM, ~650 mOsm] (N = 6), mannitol [300 mM, ~650 mOsm] (N = 3), and 2X PBS [650 mOsm] (N = 3). *p < 0.04 by Kruskal-Wallis test with non-parametric comparisons using Wilcoxon Method. d, Normalized maximum vagal firing rate to sucrose [300 mM] compared to baseline (PBS) infused into the duodenum (p = 0.0173) or ileum (p = 0.0036) (N = 4 mice per group; *p < 0.004, ANOVA with post hoc Tukey’s HSD test). e, Normalized maximum vagal firing rate to sucrose [300 mM] and sucralse [15 mM] infused intraluminally into the duodenum or proximal colon (N = 3 mice per group; *p = 0.0280, ANOVA with post hoc Tukey’s HSD test). Data are presented as mean values. Error bars = S.E.M.
Extended Data Fig. 2 | Vagal neuron response to sugars depends on intestinal Cck-labeled neuropod cells, related to Figs. 2 and 3.  

**a.** In wild-type vagal nodose neurons loaded with Fluo-4 and Fura Red, calcium activity was imaged in response to d-glucose [20 mM], sucralose [2 mM], maltodextrin [1%], and positive control KCl [50 mM] (N = 3 mice; n = 59 neurons). 

**b.** In CckCRE_TD Tomato vagal nodose neurons cultured alone, current was recorded to a +40 mV pulse, d-glucose [20 mM] stimulus, or sucralose [2 mM] stimulus (N = 2 mice; n = 15 neurons). No current response was observed to d-glucose or sucralose. Data are presented as mean values. Error bars = S.E.M. 

**c.** Left- Electrophysiology in co-cultures of vagal nodose neurons and CckCRE_TD Tomato intestinal cells (bar = 10 μm). Center- Of 18 pairs of co-cultured neurons, excitatory post-synaptic potentials were recorded to d-glucose [20 mM] (44.4%), sucralose [2 mM] (22.2%), and both (33.3%) (N = 3 mice, n = 18 pairs). Right - Peak excitatory post-synaptic currents to d-glucose [20 mM] and sucralose [2 mM] (N = 3 mice; n = 18 pairs). Data are presented as mean values. Error bars = S.E.M. 

**d.** Single cell transcriptomic data projected onto the vagal nodose atlas showing 18 nodose ganglia (NG) and 6 jugular ganglia (JG) clusters (N = 5R, 6L nodose ganglia; n = 5,507 cells). 

**e.** Violin plots from single cell transcriptomic data showing transcripts for Slc5a1 (SGLT1), Tas1r2, Tas1r3, and control Slc17a6 (VGLUT2)—a peripheral afferent marker found ubiquitously in nodose and jugular ganglion neurons.
Extended Data Fig. 3 | See next page for caption.
Extended Data Fig. 3 | Cck-labeled neuropod cells express SGLT1 in the small intestine, related to Fig. 3. a, Cck-labeled neuropod cells express SGLT1 and T1R3. b, Immunofluorescent image of small intestine tissue stained with SGLT1 (yellow). Most small intestinal epithelial cells, that is absorptive enterocytes and Cck-labeled neuropod cells (green), express SGLT1. c, Immunofluorescent image of proximal colonic tissue stained with SGLT1 (yellow). Minimal SGLT1 staining was observed in the colon. d, Fluorescent in situ hybridization (FISH) images of Cck-labeled neuropod cells in duodenal tissue. Top row—cell with expression of Cck, Tash3, and Slc5a1. Bottom row—cell with expression of Cck and Slc5a1, but not Tash3. e, Quantification of FISH results. In accordance with the single-cell qPCR results (Figs. 3b,c), 71.3 ± 0.04% of CCK+ cells only expressed transcripts for Slc5a1 while 28.7 ± 0.04% expressed transcripts for both Slc5a1 and Tash3 (N = 3 mice, n = 50 cells/mouse). Data are presented as mean values. Error bars = S.E.M. f, Normalized maximum vagal firing rate to baseline (PBS) and sucrose [300 mM] with and without SGLT2 inhibitor dapagliflozin [3 nM]. SGLT2 inhibition did not affect vagal firing in response to sucrose (N = 3 mice per group; *p = 0.0405 by ANOVA with post hoc Tukey’s HSD test). Data are presented as mean values. Error bars = S.E.M. g, Fold-change and p-values for genes shown in single cell qPCR heat map in Fig. 3b (N = 3 mice; n = 132 CckGFP+ cells, n = 66 CckGFP− cells). h–i, Heat map of gene expression in CckGFP cells by single cell qRT-PCR. h, Genes significantly different between CckGFP cells positive and negative for Slc5a1 (SGLT1) (N = 3 mice, n = 132 CckGFP cells, 104/132 Slc5a1+). i, Genes significantly different between CckGFP cells positive and negative for Tash3 (T1R3) (N = 3 mice, n = 132 CckGFP cells, 31/132 Tash3+).
Extended Data Fig. 4 | Cck-labeled neuropod cells use different neurotransmitters to distinguish sucrose from sucralose in both mouse and human, related to Fig. 4. a-c, Organoids cultured from mouse or human small intestinal tissue were stimulated with PBS, sucrose [300 mM], α-MGP [150 mM], and sucralose [15 mM]. Glutamate in the supernatant was detected using a colorimetric assay. a, In CckGFP (green) intestinal organoids, sucrose and α-MGP elicited significant glutamate release compared to PBS control, while sucralose did not. b, Human duodenal organoids contain Chromogranin-A+ cells (ChgA, green)—a validated marker for enteroendocrine cells in human tissue that co-localizes with cholecystokinin71. Human duodenal organoids release glutamate to sucrose and α-MGP, but not to sucralose or PBS control. Bars = 10 μm. c, Quantification of supernatant glutamate concentration from mouse and human organoids (mouse: N = 3 mice, n = 5-6 plates, *p < 0.05; human: N = 1 human sample, n = 3-6 plates, *p < 0.05). d, Violin plots from single cell transcriptomic data of nodose ganglia and jugular ganglia for Cckar, glutamate receptors (ionotropic (Ion.) and metabotropic (Metab.)), and ATP receptors (P2rx (Ion.) and P2ry (Metab.)) (N = 5 right, and 6 left murine nodose ganglia, n = 5,507 cells). e, Normalized vagal responses to baseline (PBS) and sucrose (left; N = 4) or sucralose (right; N = 6) before and after cholecystokinin-A receptor inhibition with devazepide [2 mg/kg]. f, Quantification of peak vagal response from e (*p < 0.0001. g-i, Time-to-peak vagal firing before and after inhibition of (g) glutamate receptors with KA/AP3 from Fig. 4b (*p < 0.03. p = 0.0031 comparing sucrose before and after KA/AP3); (h) P2 purinergic receptors with PPADS from Fig. 4d (*p < 0.05. p = 0.0039 comparing sucralose before and after PPADS); and (i) cholecystokinin-A receptors with devazepide from e. Gray vertical bars = infusion. Bold lines = mean, shaded regions/error bars = S.E.M. For vagal recordings, statistics by (g) Kruskal-Wallis test with non-parametric comparisons using Wilcoxon Method or (f, h, i) ANOVA with post hoc Tukey’s HSD test.
Extended Data Fig. 5 | Distinct neuronal pathways transmit luminal sucrose and sucralose from gut to brain. a, In anesthetized Neurod1CRE_Salsa6f mice, right nodose ganglion neurons were imaged in vivo by intravital multi-photon calcium imaging while sugars were delivered from the pylorus to the ligament of Treitz. In these mice, nodose neurons express the calcium indicator GCaMP6f. b, Representative images of nodose ganglion neurons colored by response to sucrose (top) and sucralose (middle). Merged image (bottom) shows non-overlapping populations. c, Calcium activity was imaged in response to intraduodenal sucrose [300mM] then sucralose [15mM], or vice versa. Each row indicates one neuron’s response to both sucrose and sucralose (N = 4 mice, n = 54 cells).
Extended Data Fig. 6 | Laser inhibition of duodenal Cck-labeled neuropod cells does not cause malaise or off-target effects, related to Fig. 6. a, In CRE-negative littermate controls of CckCRE_Halo mice, average traces showing sucrose [300mM] and sucralose [15mM] consumption during control 473 nm light (left) and silencing 532 nm light (right). b, Preference quantified at one hour with no laser (pre/post), control 473 nm light, and silencing 532 nm light. c, Quantification of total intake at one hour (N = 5 littermate controls; n.s. by repeated measures ANOVA). d, Activity was measured as total beam breaks in x-y plane during one-hour choice assay with control 473 nm (N = 7) or silencing 532 nm light (N = 8; n.s. by repeated measures ANOVA). e, Water and chow intake were measured during the 23 hours following the choice assay. f, Total chow and water intake in 23 hours following the one-hour choice assay with no laser (pre, post), with control 473 nm light (N = 7), or with silencing 532 nm light (N = 6). Silencing 532 nm light did not affect subsequent intake of chow or water compared to control 473 nm light (CckCRE_Halo mice, *p = 0.0030 by repeated measures ANOVA with two-tailed paired t-test post-hoc analysis). g-j, CckCRE_Halo mice underwent gavage with 300 μL of sucrose [300mM] and were tested for off-target effects of laser inhibition. Laser inhibition with silencing 532 nm light, compared to control 473 nm light, did not affect (g) gastric emptying (N = 4), (i) total gut transit time (N = 5) or (j) glucose absorption (N = 5) after sucrose gavage (CckCRE_Halo mice, n.s.). Bold line = mean, shaded regions/error bars = S.E.M.
Extended Data Fig. 7 | Glutamatergic signaling from Cck-labeled neuropod cells drives intake. **a**, CckCRE_Channelrhodopsin (CckCRE_ChR2) mice and littermate controls were given a one-bottle intake test of sucralose [15mM] for 1 hour with control 532 nm or activating 473 nm light. Laser stimulation was paired to solution consumption: for every 0.01 mL intake, mice received 5 seconds of intraluminal stimulation at 40 Hz. **b**, In littermate controls (left) or CckCRE_ChR2 mice (right), average traces show intake of sucralose plus control 532 nm light or activating 473 nm light. **c**, Stimulation of duodenal Cck-labeled neuropod cells with 473 nm light increased intake of sucralose [15mM] (N = 4 mice; *p = 0.0062, repeated-measures ANOVA with post-hoc two-tailed paired t-test). **d**, In CckCRE_ChR2 mice, ionotropic metabotropic glutamate receptor inhibitors KA/AP3 (150 μg/kg/1 mg/kg) in 10 μL/g mouse in 1M NaOH in PBS, pH=7.4) or vehicle (1M NaOH in PBS, pH=7.4) were administered intraperitoneally 25 minutes prior to the one-bottle assay as in (a). **e**, In CckCRE_ChR2 mice, average traces show intake of sucralose with vehicle (purple) or glutamate receptor inhibitor (blue) and control 532 nm light (left) or activating 473 nm light (right). **f**, Glutamate receptor inhibition reverses the increase in sucralose intake caused by optogenetic stimulation of Cck-labeled neuropod cells (N = 4 mice; *p = 0.0054, repeated-measures ANOVA with post-hoc two-tailed paired t-test). Bold line = mean, shaded regions/error bars = S.E.M.
Extended Data Fig. 8 | Cholecystokinin signaling does not mediate sucrose preference, related to Fig. 6. Circulating cholecystokinin is known to promote gallbladder emptying and slow gastric emptying in response to fat. a, Wild-type mice were anesthetized and PBS (negative control, N = 6), corn oil (positive control, N = 4), or sucrose ([300 mM], N = 7) was perfused into the duodenum and change in gallbladder volume was measured. Corn oil stimulated gallbladder emptying, while sucrose and PBS had no effect. p < 0.0001 by ANOVA. b, Wild-type mice were gavaged with 300 μL of PBS (negative control, N = 4), corn oil (positive control, N = 6), or sucrose ([300mM], N = 4) and gastric emptying was measured. Corn oil reduced gastric emptying (increased volume remaining), while sucrose and PBS had no effect. p < 0.0001 by ANOVA. c, Wild-type mice were given a two-bottle preference test between sucrose [300mM] and sucralose [15mM] for one hour. Cholecystokinin-A receptor inhibitor devazepide [2mg/kg] or vehicle (5% DMSO in PBS) was administered intraperitoneally (10 μL/g mouse) 30 minutes prior to assay. d, Preference for sucrose over sucralose (left) and sugar intake (right) during the one-hour assay with vehicle or devazepide. Preference was unchanged by devazepide compared to vehicle. Sucrose intake trended towards increasing with devazepide (N = 4 mice per group, n.s.). e, Average traces show sucrose and sucralose intake with intraperitoneal injection of vehicle (left) or cholecystokinin-A receptor inhibitor devazepide (right). Bold line = mean, shaded regions/error bars = S.E.M.
Extended Data Fig. 9 | Duodenal local dose of glutamate receptor inhibitors does not impact sucrose preference when delivered systemically.

**a**, Wild-type mice were given a two-bottle preference test between sucrose [300mM] and sucralose [15mM] for one hour. Local dose ionotropic/metabotropic glutamate receptor inhibitors KA/AP3 ([15ng/kg]/[0.1μg/kg] in 10μL/g mouse in 1M NaOH in PBS, pH=7.4) or vehicle (1M NaOH in PBS, pH=7.4) was administered intraperitoneally 10 minutes prior to assay. **b**, Average traces show sucrose and sucralose consumption with intraperitoneal injection of vehicle (left) or local dose glutamate receptor inhibitors KA/AP3 (right). **c**, Preference for sucrose over sucralose (left) and sugar intake (right) during the one-hour assay with vehicle or KA/AP3. Preference and intake was unchanged by systemic administration of local dose glutamate receptor inhibition compared to vehicle (N = 4 mice per group, n.s.). Bold line = mean, shaded regions/error bars = S.E.M.
Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
  - Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
  - Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

Software used in data collection: Signal Express (NI; https://ni.com, version 16.0.1); pClamp (Axon Instruments; Software Version 10.7); ZEN 2 - Blue Edition (Zeiss; https://www.zeiss.com); PhenoMaster software (TSE Systems Inc.; software version 6.6.9)

Data analysis

Software used in data analysis: ImageJ/Fiji (Schneider et al 2012; https://imagej.nih.gov/ij/, version 2.3.0); MATLAB (MathWorks; https://www.mathworks.com, version R2021a 9.10); RStudio (R Consortium; https://www.r-project.org, version 2.10); JMP Pro (JMP from SAS, https://www.jmp.com, version 16); Spike Tailor (Mathworks; Kaelberer et al., 2018); Seurat (R Consortium; Stuart et al., 2019, version 3.1.0); Biomark- RealTime PCR Analysis (Fluidigm; https://www.fluidigm.com/software, PN 101-6793); Qlucore Omics Explorer (Qlucore; https://www.qlucore.com/omics-explorer, version 3.6)

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

The source data that support the findings of this study are available from the corresponding author upon request. The mm10 mouse reference genome available from GENCODE vM23/Ensembl 98. Single cell sequencing datasets are available on the NIH GEO database (GSE185173).
Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- [x] Life sciences
- [ ] Behavioural & social sciences
- [ ] Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](http://nature.com/documents/nr-reporting-summary-flat.pdf)

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

| Sample size | No statistical methods were used to pre-determine sample sizes but our sample sizes are similar to those reported in previous publications studying ingestive behavior in mouse models (Han et al., Cell, 2018; Tan et al., Nature, 2020; Sclafani & Ackroff, Physiol. Behav., 2017). |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Data exclusions | - For vagal nerve recordings: Throughout experiments, sucrose response was used as a positive control. For all nutrient and laser stimulation conditions, data were excluded if a stable sucrose response was not seen throughout the recording session.  
- For single cell qPCR: All cells not meeting quality measures or having no detected transcripts for either housekeeping gene (Gapdh or Actb1) were excluded from analysis (48 positive cells, 24 negative cells were excluded).  
- For calcium imaging and patch clamp electrophysiology: Each recording session concluded with 45 mM KCl as an activity control (KCl concentration was achieved by substituting for NaCl, and not an addition of more KCl). A response to KCl was defined as a ratio > 10% increase above baseline. Cells that did not reach this KCl threshold were not included in analyses.  
- For in vivo calcium imaging of vagal nodose neurons: The predetermined exclusion criteria for neurons was a response to mannitol [300mM] because this meant the neuron was responsive to osmolarity instead of just sugar.  
- For optogenetic behavior studies: Only mice who completed all tests and whose fiber optic device had appropriate power/placement at completion were included in analysis. For two-bottle studies, mice that did not have a side preference were included.  
- For pharmacologic behavior studies. Only mice who completed all tests, did not have a side preference, and whose catheter had appropriate placement and patency at completion were included in analysis. |
| Replication | - For vagal cuff experiments, the response to positive control sucrose was tested and replicated in between ligands to ensure within subject reproducibility. If the response changed substantially, the inclusion criterion was not met and therefore, the experiment was terminated. The vagal response to sucrose and sucralse was reproducible across at least 2 users.  
- For in vitro calcium imaging and patch clamp electrophysiology, the response to stimuli within the same cell was not replicated due to limitations of cell viability with repeated applications. To ensure reproducibility, experiments were conducted across several sessions and included at least 2 independent biological replicates.  
- For in vivo calcium imaging, each stimulant was perfused twice per mouse, leading to similar results. To ensure reproducibility, experiments were conducted across several sessions and included 4 independent biological replicates.  
- For single cell qPCR, experiments were repeated three times using three biological replicates. The results of individual experiments were similar.  
- For behavior experiments, response to optogenetic or pharmacologic inhibition was not replicated within subject because the durability of the implants was limited and multiple experiments were required from each mouse. To ensure reproducibility, mice across at least 3 litters were used for each experiment. |
| Randomization | Standardized randomization was not performed for in vitro or in vivo experiments. For vagal cuff experiments, sucrose 300mM was used as a positive control and the order of the subsequent ligands was random within each mouse. For in vitro calcium imaging experiments, in vivo calcium imaging experiments, and patch clamp electrophysiology, the order of the experimental stimuli was alternated to control for potential order effects. All behavioral studies were counterbalanced across age and sex to control for variables including position in cage, order effect, and handedness. |
| Blinding | Experimenters were not blinded to treatment condition, genotype, or outcome due to the need for the experimenter to give the desired test ligand or treatment. |

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.
Materials & experimental systems

- Involved in the study
  - Antibodies
  - Eukaryotic cell lines
  - Palaeontology and archaeology
  - Animals and other organisms
  - Human research participants
  - Clinical data
  - Dual use research of concern

Methods

- Involved in the study
  - ChIP-seq
  - Flow cytometry
  - MRI-based neuroimaging

Antibodies

| Antibodies used          | Validation                                                                                   |
|-------------------------|---------------------------------------------------------------------------------------------|
| - For immunohistochemistry: Anti-SGLT1 antibody (host = rabbit) (Abcam; Cat#ab14686); Anti-GFP antibody (host = chiken) (Abcam; Cat#ab13970); Alexa Fluor 488 AffiniPure F(ab') Fragment Donkey Anti-Rabbit IgG (H+L) (Jackson ImmunoResearch; Cat#711-546-152; RRID#AB_2340619); Cy3 AffiniPure F(ab') Fragment Donkey Anti-Rabbit IgG (H+L) (Jackson ImmunoResearch; Cat#711-166-152; RRID#AB_2313568); Alexa Fluor 488 AffiniPure F(ab') Fragment Donkey Anti-Chicken IgG (H+L) (Jackson ImmunoResearch; Cat#703-546-155; RRID#AB_2340376) | Anti-SGLT1 antibody was commercially validated in human enterocytes, heart and skeletal muscle tissues. The antibody was then validated for this study in murine enterocytes as positive control. Anti-GFP antibody was commercially validated in mouse tissue against recombinant fragment. |

Animals and other organisms

Policy information about studies involving animals: ARRIVE guidelines recommended for reporting animal research

| Laboratory animals         | Wild animals
|---------------------------|---------------------------|
| Male and female adult mice aged 6-20 weeks were used in all experiments. Mice were group housed in Duke University’s Division of Laboratory Animal Resources, where they were kept on a 12-hour light-dark cycle (0700-1900) with access to water and standard mouse chow (Purina 5001) ad-libitum, unless otherwise indicated in the manuscript Methods. The facility maintained an ambient temperature of 18-23°C and humidity of 40-60%. Mice used were: C57BL/6J (wild-type) (Jackson Lab; Stock #000664); Swiss Webster (wild-type) (Charles River; Stock #024); CckGFP (background = Swiss Webster) (Rodger Liddle, M.D.; Wang et al., 2010); CckCRE (background = C57BL/6J) (Jackson Lab; Stock #012706); Neurod1CRE (background = C57BL/6J) (Jackson Lab; Stock #028364); LSL_tdTomato (background = C57BL/6J) (Jackson Lab; Stock #007914); LSL_Halo-YFP (background = C57BL/6J) (Jackson Lab; Stock #014539); LSL_ChR2-tdTomato (background = C57BL/6J) (Jackson Lab; Stock #012567); LSL_Salsa6f (background = C57BL/6J) (Jackson Lab; Stock #031968) | No wild animals were used in the study. |

| Field-collected samples | No field-collected samples were used in the study. |

| Ethics oversight         | All experiments on mice were performed following approval by the Institutional Animal Care and Use Committee at Duke University Medical Center under the protocol A280-18-12. |

Human research participants

Policy information about studies involving human research participants

| Population characteristics | Human samples were received de-identified. Patient characteristics were unknown. |
|-----------------------------|--------------------------------------------------------------------------------|

| Recruitment                 | Participants were recruited through the Duke University Medical Center Biorepository and Precision Pathology Center (BRPC) under the Institutional Review Board (IRB) protocol Pro00035974 via anonymous tissue release. |

| Ethics oversight            | Human duodenal samples were obtained from the Duke University Medical Center Biorepository and Precision Pathology Center (BRPC) under the Institutional Review Board (IRB) protocol Pro00035974 via anonymous tissue release. Per this protocol, informed consent was obtained from all study participants. All samples were deidentified and all links to additional patient information were broken prior to receipt of fresh surgical specimens. |

Note that full information on the approval of the study protocol must also be provided in the manuscript.